信迪利单抗联合XELOX方案化疗治疗晚期胃癌患者的临床疗效  

Clinical efficacy of sintilimab combined with XELOX regimen chemotherapy in patients with advanced gastric cancer

作　　者：麻青 刘京 王松琪 MA Qing;LIU Jing;WANG Songqi(Department of Oncology,Hebi People’sHospital,Hebi 458030,He’nan,China)

机构地区：[1]鹤壁市人民医院肿瘤内科,河南鹤壁4580300

出　　处：《癌症进展》2024年第22期2529-2533,共5页Oncology Progress

摘　　要：目的 探讨信迪利单抗联合奥沙利铂^(+)卡培他滨(XELOX)方案化疗治疗晚期胃癌患者的临床疗效。方法 根据治疗方法的不同将78例晚期胃癌患者分为常规组和观察组,每组39例,常规组患者采取XELOX方案化疗,观察组患者采取信迪利单抗联合XELOX方案化疗。比较两组患者的临床疗效、炎性因子[C反应蛋白(CRP)、白细胞介素(IL)-6、肿瘤坏死因子-α(TNF-α)]水平、肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、糖类抗原72-4(CA72-4)、甲胎蛋白(AFP)、组织多肽特异性抗原(TPS)]水平、T淋巴细胞亚群水平(CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+))、营养指标[总蛋白(TP)、转铁蛋白(TRF)、前白蛋白(PAB)、白蛋白(ALB)]及不良反应发生情况。结果 观察组患者的临床疗效优于常规组,客观缓解率(ORR)高于常规组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CRP、IL-6、TNF-α、CEA、CA19-9、CA125、CA72-4、AFP及TPS水平均低于本组治疗前,CD3^(+)、CD4^(+)、TRF、ALB、PAB、TP水平及CD4^(+)/CD8^(+)均高于本组治疗前,观察组患者CRP、IL-6、TNF-α、CEA、CA19-9、CA125、CA72-4、AFP及TPS水平均低于常规组,CD3^(+)、CD4^(+)、TRF、ALB、PAB、TP水平及CD4^(+)/CD8^(+)均高于常规组,差异均有统计学意义(P﹤0.05)。两组患者各不良反应发生率比较,差异均无统计学意义(P﹥0.05)。结论 信迪利单抗联合XELOX方案化疗治疗晚期胃癌患者可提高临床疗效,减轻炎性反应,降低肿瘤标志物水平,增强免疫功能,改善营养指标,且具有一定的安全性。Objective To explore the clinical efficacy of sintilimab combined with oxaliplatin^(+)capecitabine(XE-LOX)regimen chemotherapy in patients with advanced gastric cancer.Method According to different treatment meth-ods,78 patients with advanced gastric cancer were divided into conventional group and observation group,with 39 cases in each group.Patients in conventional group received XELOX regimen chemotherapy,while patients in observation group received sintilimab combined with XELOX regimen chemotherapy.The clinical efficacy,inflammatory factors[C-reactive protein(CRP),interleukin(IL)-6,tumor necrosis factor-α(TNF-α)]levels,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125),carbohydrate antigen 72-4(CA72-4),alpha fetoprotein(AFP),tissue polypeptide specific antigen(TPS)]levels,T lymphocyte subsets levels(CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)),nutritional indexes[total protein(TP),transferritin(TRF),prealbumin(PAB),albumin(ALB)]and adverse reactions were compared between the two groups.Result The clinical efficacy of the observation group was better than that of the conventional group,and the objective response rate(ORR)was higher than that of the conventional group,and the differences were statistically significant(P<0.05).After treatment,the levels of CRP,IL-6,TNF-α,CEA,CA19-9,CA125,CA72-4,AFP and TPS in both groups were lower than those before treatment,and the levels of CD3^(+),CD4^(+),TRF,ALB,PAB,TP and CD4^(+)/CD8^(+)were higher than those before treatment,the levels of CRP,IL-6,TNF-α,CEA,CA19-9,CA125,CA72-4,AFP and TPS in observation group were lower than those in conventional group,and the levels of CD3^(+),CD4^(+),TRF,ALB,PAB,TP and CD4^(+)/CD8^(+)were higher than those in conventional group,the differences were statistically significant(P<0.05).There were no significant differences in the incidences of adverse reactions be-tween the two groups(P>0.05).Conclusion Sintilimab combined with XELOX regimen chemotherapy can improve the clinical efficac

关 键 词：晚期胃癌 信迪利单抗 临床疗效 炎性因子 肿瘤标志物 

分 类 号：R735.2[医药卫生—肿瘤]